About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 50 record(s)
Req # A-2021-000382
All registration, renewal, amendment or discontinuance applications and Pest Management Regulatory Agency (PMRA) responses for registered Chlorpyrifos products from the years 2006 to 2021.Organization: Health Canada
September 2021
Req # A-2021-000401
The list of all suppliers or importers of protective masks or medical masks (surgical and intervention masks) containing nanoform graphene in Canada for the period of January 1, 2020 to January 1, 2021.Organization: Health Canada
September 2021
Req # A-2021-000468
Adverse Drug Reaction (ADR) for ALEMTUZUMAB. Report number: E2B_03391205.Organization: Health Canada
September 2021
Req # A-2021-000480
The department's Corporate Risk Profile (sometimes entitled Departmental Risk Profile or the Integrated Risk Profile).Organization: Health Canada
September 2021
Req # A-2021-000503
Adverse Drug Reaction (ADR) for ALEMTUZUMAB. Report number: E2B_03393973.Organization: Health Canada
September 2021
Req # A-2021-000548
Adverse Drug Reaction (ADR) for ROSUVASTATIN CALCIUM. Report number: E2B_03745892.Organization: Health Canada
September 2021
Req # A-2021-000563
Adverse Reaction Reports (AERs) for ALEMTUZUMAB. Report numbers: E2B_03394016, E2B_03393987, E2B_03387869, E2B_03391239, E2B_03454376, E2B_03387914, E2B_03391267, E2B_03396602, E2B_03387903, E2B_03391347, E2B_03391236, E2B_03393768, E2B_03392200, E2B_03393774, E2B_03391849, E2B_03391274, E2B_03463382, E2B_03468912, E2B_03387890.Organization: Health Canada
September 2021
Req # A-2021-000634
Adverse Drug Reaction (ADR) for METFORMIN HYDROCHLORIDE. Report number: E2B_03420918.Organization: Health Canada
September 2021
Req # A-2021-000650
Adverse Reaction Reports (AERs) for CYCLOPHOSPHAMIDE. Report numbers: 918864, 918869, 918929.Organization: Health Canada
September 2021
Req # A-2021-000756
Health Canada’s total spending on translation services under Request for Standing Offers (RFSO), Translation Services, Requisition Reference no. 1000211711 between July 1st 2019 to June 30 2020 and between July 1st 2020 and June 30th 2021. Detailed list of the suppliers used under this RFSO along with the dollar amount spent with each supplier.Organization: Health Canada
September 2021